Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.

What Was Tested

This registered not phased trial tested Liraglutide for fat loss, obesity & body recomposition.

Their primary objective is to assess the effect of Liraglutide on weight loss in patients who have undergone secondary bariatric surgeries.

The researchers set out to assess if Liraglutide is a viable option to augment weight loss in said category.

It had two arms (groups): Liraglutide (experimental) and Control (no intervention).

Patients with no weight loss drug intervention after bariatric surgery.

The registry classes the interventions as drug.

Who Took Part

The registry lists 60 planned participants were the target.

It was open to people of any sex.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Undergone primary bariatric surgery. Need secondary bariatric surgery due to either weight regain (regained weight to have BMI \> 35) or medical associated diseases.

The full record lists 2 inclusion and 7 exclusion criteria; among the exclusions: prior use of glp-1 agonist; past history of pancreatitis; personal or family history of medullary thyroid cancer.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

The fat loss, obesity & body recomposition participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.

The Liraglutide group and the comparison group ran side by side rather than switching.

Blinding on both sides kept the fat loss, obesity & body recomposition participants and researchers unaware of who received Liraglutide.

Those kept unaware of assignments: participant and investigator.

It started in 2022-03-10 with completion listed for 2022-09.

It ran at 1 site in Egypt.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Percentage Total weight loss (time frame: 6 months). Percentage Excess body weight loss (time frame: 6 months).

It also tracked 10 secondary outcomes, for example Comorbidities, Weight, BMI, HbA1C, Fasting Blood Glucose (FBG) and HOMA-IR.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Liraglutide in 60 people with fat loss, obesity & body recomposition.

Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Liraglutide compound page, Fat loss, obesity & body recomposition research.